The Foundation for Food and Agriculture Research (FFAR) has launched a research program to explore a vaccine against New World screwworm, a parasitic fly whose larvae infest living tissue of livestock and, occasionally, other mammals.

The announcement arrives as the pest moves north. New World screwworm had been eliminated from the United States decades ago through the sterile insect technique, in which irradiated male flies are released to collapse the wild population. That eradication held for years across North and Central America. Recent detections in southern Mexico, on the corridor that leads toward the U.S. border, have reopened the question of how to hold the line — and FFAR is betting that a vaccine can add a second tool beside fly release programs.

Why a vaccine, and why now?

New World screwworm flies lay eggs in open wounds. The larvae that hatch feed on living flesh, a condition called myiasis, which can kill cattle, sheep, goats and other livestock if untreated. Each infested animal can serve as a breeding site for the next generation of flies, so a handful of cases in a herd can multiply quickly.

Control has long depended on two approaches: surveillance and the sterile insect technique. The sterile-fly method works, but it requires sustained funding, rearing facilities and continuous aerial releases over large territories. A vaccine, if successful, would shift part of the defense onto the animal itself. Ranchers would gain protection that travels with the herd, independent of fly-release logistics.

What the research program involves

FFAR, a nonprofit established by the 2014 U.S. farm bill to partner public research funding with private dollars, has made the screwworm vaccine a research priority. The foundation's model puts federal funds alongside matching contributions from industry and academic partners, which means the program is expected to draw in veterinary schools, livestock producer groups and animal-health companies as participants.

According to the report from Feed Strategy, which carried the announcement, the work aims to identify vaccine candidates capable of protecting livestock against screwworm myiasis. The precise antigens, trial design and species enrolled have not yet been detailed publicly, and FFAR has not announced a timeline for candidate trials.

What is at stake for cattle producers

For U.S. cattle producers, the economics are straightforward. Screwworm myiasis cuts weight gain, damages hides, forces treatment labor and, in outbreak scenarios, triggers trade restrictions. The last U.S. eradication campaign, completed in 1966, came only after years of losses across southern ranching states. Reintroduction today would move quickly through warm-region herds, where wounds from branding, castration and calving give flies entry points.

Mexico's cattle industry has already felt the current outbreak, with movement controls and surveillance steps imposed in affected states. U.S. animal health authorities have responded by tightening import requirements along the southern border — a reminder that screwworm control is as much a trade and regulatory question as a biological one.

Public health, briefly

New World screwworm can infest humans, though rarely. Cases occur where people work close to infested animals in endemic regions. A livestock vaccine would reduce the animal reservoir that sustains fly populations, which in turn lowers human exposure risk. Any resulting veterinary vaccine would proceed through the U.S. Department of Agriculture's regulatory pathway, since USDA — not FDA CVM — oversees biologics for food-producing animals. No screwworm vaccine currently holds licensure in the United States.

The road from grant to syringe

Vaccine development for an arthropod parasite is hard. The parasite's life stage that attacks the host — the larva feeding in a wound — presents a moving immunological target, and inducing protective immunity at the wound site, rather than in the bloodstream, has frustrated earlier attempts against related parasites. FFAR's program will need to clear those scientific barriers, then move candidates through challenge trials in livestock, a process measured in years.

Producers and veterinarians watching the program should track two milestones: the announcement of funded research teams with named antigen targets, and the first published results from controlled challenge studies. Until then, sterile fly releases and border surveillance remain the only working defenses, and the screwworm's northward progress will keep setting the urgency of both.